---
layout: default
title: Acer Saccharinum Pollen Alnus Rhombifolia Pollen B
parent: 僅模型預測 (L5)
nav_order: 77
evidence_level: L5
indication_count: 0
---

# Acer Saccharinum Pollen Alnus Rhombifolia Pollen B
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Tree Pollen Allergen Mixture: Preliminary Assessment — No Repurposing Predictions Available

## One-Sentence Summary

This product is a multi-component tree pollen allergen extract composed of 9 species (silver maple, white alder, sweet birch, shagbark hickory, white ash, American sycamore, white poplar, white oak, and cedar elm), typically used in allergen immunotherapy for IgE-mediated respiratory allergies.
The TxGNN model was **unable to generate repurposing predictions** for this candidate, most likely because no DrugBank ID could be mapped and the multi-component mixture cannot be represented as a single node in the knowledge graph.
With **no clinical trials or publications** identified, and no active market authorizations, a standard repurposing evaluation cannot proceed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Allergen immunotherapy (tree pollen allergy desensitization) |
| Predicted New Indication | Not available — TxGNN returned no predictions |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — no predictions generated; model pipeline did not complete |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

This product is a subcutaneous or sublingual allergen immunotherapy (AIT) formulation containing whole or extracted pollen from 9 tree species: silver maple (*Acer saccharinum*), white alder (*Alnus rhombifolia*), sweet birch (*Betula lenta*), shagbark hickory (*Carya ovata*), white ash (*Fraxinus americana*), American sycamore (*Platanus occidentalis*), white poplar (*Populus alba*), white oak (*Quercus alba*), and cedar elm (*Ulmus crassifolia*). Products of this class are classically indicated for desensitization in patients with allergic rhinitis, allergic conjunctivitis, and/or allergic asthma triggered by tree pollen. The proposed mechanism involves repeated antigen exposure to shift the immune response from Th2-dominant IgE-mediated hypersensitivity toward immune tolerance, typically via induction of regulatory T cells and IgG4 blocking antibodies.

Currently, detailed mechanism of action data is not available in DrugBank, and no DrugBank ID was successfully mapped to this multi-component mixture. Because the TxGNN knowledge graph model requires a single, mappable drug entity as input, a multi-allergen preparation cannot be directly processed through the standard pipeline. This is a structural limitation of applying small-molecule-oriented repurposing tools to biologic immunotherapy products.

It is worth noting that the question of "repurposing" an allergen immunotherapy product is conceptually distinct from repurposing a conventional drug. Emerging research does explore broader immunological effects of AIT (e.g., cross-tolerance, reduction of new sensitizations, potential asthma prevention), but these would require specialized evidence frameworks rather than standard TxGNN output.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No authorizations are registered for this product.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This multi-component pollen allergen product could not be processed by the TxGNN pipeline due to the absence of a DrugBank ID mapping and the intrinsic incompatibility of multi-allergen biologic mixtures with knowledge-graph-based small-molecule repurposing models. Without predictions, evidence, or active regulatory registrations, there is no actionable repurposing signal to evaluate at this stage.

**To proceed, the following is needed:**
- Determine whether each individual pollen component should be evaluated separately, or whether a surrogate small-molecule (e.g., a benchmark AIT adjuvant) should serve as a proxy
- Identify or register DrugBank IDs for individual allergen components (e.g., *Betula lenta* birch allergen Bet v 1) to enable knowledge graph queries
- Clarify the regulatory pathway: confirm whether any equivalent product has US FDA approval (e.g., under BLA/NDA for standardized allergen extract), which would establish a safety and indication baseline
- Assess whether the TxGNN pipeline is the appropriate tool for allergen biologics, or whether a different computational framework (e.g., epitope-based immunoinformatics) should be used instead
- Obtain package insert or prescribing information to close the blocking safety data gap (DG001)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

